These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19069157)

  • 21. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
    Mignani R; Cagnoli L
    J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.
    Oder D; Liu D; Hu K; Üçeyler N; Salinger T; Müntze J; Lorenz K; Kandolf R; Gröne HJ; Sommer C; Ertl G; Wanner C; Nordbeck P
    Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 29018006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression.
    Paliouras C; Aperis G; Lamprianou F; Ntetskas G; Roufas K; Alivanis P
    Nefrologia; 2015; 35(6):578-81. PubMed ID: 26384850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ocular findings in Fabry's disease].
    Kuzman T; Juri J; Mrsić M; Jeren-Strujić B; Mandić Z; Sikić J
    Acta Med Croatica; 2006; 60(2):163-6. PubMed ID: 16848212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current status and future prospect of enzyme replacement therapy for Fabry disease].
    Ohashi T
    Rinsho Shinkeigaku; 2019 Jun; 59(6):335-338. PubMed ID: 31142708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
    Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
    Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High incidence of thrombosis in Fabry's disease.
    Utsumi K; Yamamoto N; Kase R; Takata T; Okumiya T; Saito H; Suzuki T; Uyama E; Sakuraba H
    Intern Med; 1997 May; 36(5):327-9. PubMed ID: 9213168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fabry disease female proband with clinical manifestations similar to hypertrophic cardiomyopathy.
    Teragaki M; Tanaka A; Akioka K; Lan HT; Nishi Y; Yamano T; Yoshikawa J
    Jpn Heart J; 2004 Jul; 45(4):685-9. PubMed ID: 15353880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.
    Schaefer E; Mehta A; Gal A
    Acta Paediatr Suppl; 2005 Mar; 94(447):87-92; discussion 79. PubMed ID: 15895718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel alpha-galactosidase A mutation in a female with recurrent strokes.
    Tuttolomondo A; Duro G; Miceli S; Di Raimondo D; Pecoraro R; Serio A; Albeggiani G; Nuzzo D; Iemolo F; Pizzo F; Sciarrino S; Licata G; Pinto A
    Clin Biochem; 2012 Nov; 45(16-17):1525-30. PubMed ID: 22820434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Changing Landscape of Fabry Disease.
    Svarstad E; Marti HP
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):569-576. PubMed ID: 32132142
    [No Abstract]   [Full Text] [Related]  

  • 33. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
    Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
    Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Contribution of genotyping in Fabry's disease].
    Froissart R; Piraud M; Maire I
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S275-8. PubMed ID: 21211679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
    Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
    Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives].
    Germain DP
    Rev Med Interne; 2000 Dec; 21(12):1086-103. PubMed ID: 11191676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
    Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
    Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson-Fabry disease.
    Stamerra CA; De Feo M; Castelli V; d'Angelo M; Cimini A; Grassi D; Ferri C
    Eur J Hum Genet; 2021 Feb; 29(2):218-224. PubMed ID: 32948848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.